GlassScriptPhysician profile
Mohammed Z Mohialdeen
NPI 1841643210
$316.45
in general payments reported to CMS, 2019-2025
11 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.17 · 2021: $18.19 · 2022: $12.28 · 2024: $30.77 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $95.41 | 2025 | Tarpeyo |
| Kerecis Limited | $39.38 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Novartis Pharmaceuticals Corporation | $30.77 | 2024 | |
| Ethicon US, LLC | $30.47 | 2021-2022 | |
| Glaxosmithkline, LLC. | $21.93 | 2025 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $20.19 | 2025 | Jynarque |
| Vifor Pharma, INC. | $20.17 | 2020 | |
| Akebia Therapeutics INC | $18.57 | 2025 | Vafseo |
| Novo Nordisk INC | $18.43 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.86 | 2025 | Jardiance |
| Travere Therapeutics, INC. | $6.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Mohialdeen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.